Michael Powell

Mike Powell, Ph.D., has more than 25 years of pharmaceutical development experience, and he has focused interest in clinical-stage product companies, particularly in the oncology, endocrine, and neurology areas. He joined Sofinnova Ventures as a General Partner in 1997 as a member of the Life Science investment team. Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including an 1,100–page treatise on vaccine design. Mike was an early investor in Actelion (SWX: ATLN), InterMune (Nasdaq: ITMN), Anesiva (Nasdaq: ANSV), Orexigen Therapeutics (Nasdaq: OREX), Seattle Genetics (Nasdaq: SGEN), and Threshold Pharmaceuticals (Nasdaq: THLD), as well as several private companies such as Ascenta and Trius Therapeutics. Mike is currently Board President of AVAC (AIDS Vaccine Advocacy Coalition), a past Advisor to the Bill and Melinda Gates Foundation, a Strategic Advisor to One World Health, and a Founding Venture Advisory Board member of the IAVI Innovation Fund. He flies too much, but he loves it.

Mike was Group Leader of Drug Delivery at Genentech (1990-97) where his focus was developing new therapeutics. In 1987 he was part of the founding team of Cytel; as Director of Product Development, he was responsible for the company's early growth, which culminated in a successful IPO. Before this he was Scientist and Project Team Leader at Syntex Research. Mike had the honor of being the first scientist from the biotechnology industry to be elected a Fellow of the American Association of Pharmaceutical Scientists. He was also an Adjunct Professor at the University of Kansas, an Editorial Board member of J. Pharm. Sci., and a Scientific Advisor to the Controlled Release Society.

He received his Ph.D. in Physical Chemistry from the University of Toronto in 1981, and completed his post-doctorate work in Bioorganic Chemistry at the University of California, where he was subsequently a faculty member (1981-84).

Michael Powell is the Executive Partner at Omega Funds, based in United States, North America. With a background in Financial Services, Michael Powell has a rich history of leadership and innovation. Michael Powell studied Ph.D Physical Chemistry @ University of Toronto. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.